David Sullivan

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

A Keech, R. John Simes, Philip J. Barter et al. · The Lancet · 2005 · 3.2K citations

Diabetes Management, Cardiovascular Disease, Health Policy +9

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +11

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Erik S.G. Stroes, David Colquhoun, David Sullivan et al. · Journal of the American College of Cardiology · 2014 · 525 citations · Full text

Inflammation, Lipid Disorder, Statin Intolerance +8

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

David Sullivan, Anders Olsson, Robert C. Scott et al. · JAMA · 2012 · 445 citations

Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients

Mika Hilvo, Peter J. Meikle, Eva Ringdal Pedersen et al. · European Heart Journal · 2019 · 287 citations · Full text